ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended			0 Months Ended	3 Months Ended	0 Months Ended
	Dec. 31, 2014 item	Dec. 31, 2013	Dec. 31, 2012	Jan. 15, 2015	Dec. 31, 2014	Oct. 18, 2013
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of product candidates under clinical development	1
Summary Of Significant Accounting Policies
Royalty and milestone payments received		$ 240,500,000
Outstanding balance of the liability recognized in Non-cash royalty revenue	242,808,000	18,104,000
Cash discount (as a percent)	2.00%
Discount reimbursement period after filling of prescription subject to discount	1 month
Accounts payable and accrued liabilities	52,686,000	34,935,000			52,686,000
Liability related to the sale of future royalties and milestones		56,357,000
Asset Purchase Agreement
Payment to acquire rights of pharmaceuticals products and certain related assets		52,725,000	26,435,000
Restatement
Summary Of Significant Accounting Policies
Accounts payable and accrued liabilities		(6,900,000)
Liability related to the sale of future royalties and milestones		6,900,000
Janssen Pharmaceuticals, Inc. | Subsequent event
Asset Purchase Agreement
Payment to acquire rights of pharmaceuticals products and certain related assets				1,050,000,000
Cash deposit to JPMorgan Chase Bank,N.A.,(Escrow Agent)				500,000,000
Janssen Pharmaceuticals, Inc. | Subsequent event | Forecast
Asset Purchase Agreement
Amount of capital raised, net of fees				550,000,000
Minimum
Summary Of Significant Accounting Policies
Discount taken off period after the quarter in which product shipped to the customer	1 month
Period after the quarter in which prescription is filled for paying rebate	2 months
Minimum | Managed Care Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	1 month
Minimum | Medicare Part D Coverage Gap Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	2 months
Maximum
Summary Of Significant Accounting Policies
Product return period prior to expiration	6 months
Period after expiration for accepting unsalable product	12 months
Discount taken off period after the quarter in which product shipped to the customer	2 months
Period after the quarter in which prescription is filled for paying rebate	3 months
Maximum | Managed Care Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	3 months
Maximum | Medicare Part D Coverage Gap Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	3 months
Gralise | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
Gralise | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
Zipsor
Summary Of Significant Accounting Policies
Product shelf-life	36 months
500mg Glumetza
Summary Of Significant Accounting Policies
Product shelf-life	48 months
1000mg Glumetza | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
1000mg Glumetza | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
CAMBIA | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
CAMBIA | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	48 months
Lazanda | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
Lazanda | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
Liability related to sale of future royalties
Summary Of Significant Accounting Policies
Outstanding balance of the liability recognized in Non-cash royalty revenue					146,956,000
Liability related to sale of future royalties | PDL BioPharma
Summary Of Significant Accounting Policies
Royalty and milestone payments received						$ 240,500,000